Skip to the page

Data / Drug companies / Ajanta Pharma USA Inc.

Ajanta Pharma USA Inc.: 174 products in the FDA NDC directory, labeler code 27241

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Ajanta Pharma USA Inc. (labeler code 27241) lists 174 products in the FDA National Drug Code Directory, covering 62 finished drugs by generic name. By type: 174 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 14, 2026.

The request: Watch Ajanta Pharma USA Inc. (FDA labeler code 27241): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
27241
Products in commercial distribution
174
Packages
270
Finished drugs by generic name
62
Prescription products
174
Over the counter products
0
Flagged as original packager
147 of 147 products that carry the flag
Started marketing in the last 12 months
14
Earliest marketing start
March 28, 2014
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)174100%

Products by type

TypeProductsShare
Prescription drugs174100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet7342%
Tablet, extended release2715.5%
Capsule2313.2%
Capsule, extended release137.5%
Tablet, film coated126.9%
Capsule, delayed release63.4%
For suspension52.9%
Tablet, orally disintegrating42.3%
Tablet, delayed release21.1%
Powder, for suspension21.1%
Tablet, chewable21.1%
Granule10.6%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Haloperidol27241-269TabletGeneric drugs (ANDA)September 14, 2026
Haloperidol27241-268TabletGeneric drugs (ANDA)September 14, 2026
Haloperidol27241-267TabletGeneric drugs (ANDA)September 14, 2026
Haloperidol27241-266TabletGeneric drugs (ANDA)September 14, 2026
Haloperidol27241-265TabletGeneric drugs (ANDA)September 14, 2026
Haloperidol27241-264TabletGeneric drugs (ANDA)September 14, 2026
Tofacitinib27241-270Tablet, extended releaseGeneric drugs (ANDA)June 3, 2026
Ivermectin27241-293TabletGeneric drugs (ANDA)April 7, 2026
Dapagliflozin27241-152TabletGeneric drugs (ANDA)April 6, 2026
Dapagliflozin27241-151TabletGeneric drugs (ANDA)April 6, 2026
Methazolamide27241-247TabletGeneric drugs (ANDA)February 9, 2026
Methazolamide27241-246TabletGeneric drugs (ANDA)February 9, 2026
Prucalopride27241-295TabletGeneric drugs (ANDA)January 16, 2026
Prucalopride27241-294TabletGeneric drugs (ANDA)January 16, 2026
Topiramate27241-300Capsule, extended releaseGeneric drugs (ANDA)September 2, 2025
Topiramate27241-299Capsule, extended releaseGeneric drugs (ANDA)September 2, 2025
Topiramate27241-298Capsule, extended releaseGeneric drugs (ANDA)September 2, 2025
Topiramate27241-297Capsule, extended releaseGeneric drugs (ANDA)September 2, 2025
Topiramate27241-296Capsule, extended releaseGeneric drugs (ANDA)September 2, 2025
Terazosin27241-291CapsuleGeneric drugs (ANDA)May 12, 2025
Terazosin27241-290CapsuleGeneric drugs (ANDA)May 12, 2025
Terazosin27241-289CapsuleGeneric drugs (ANDA)May 12, 2025
Terazosin27241-288CapsuleGeneric drugs (ANDA)May 12, 2025
Theophylline27241-272Tablet, extended releaseGeneric drugs (ANDA)March 26, 2025
Metoprolol tartrate and hydrochlorothiazide27241-302TabletGeneric drugs (ANDA)March 15, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.